Patient history:

• Leon was diagnosed with SM-AHN (low-risk MDS) 3 months ago
• Initiated treatment with a tyrosine kinase inhibitor but discontinued due to tolerability issues
• Baseline platelet count was 65 x 10⁹/L

Introduction of AYVAKYT:

• The patient initiated AYVAKYT 200 mg once daily, and platelet counts were monitored every 2 weeks for the first 8 weeks as per dosing guidelines¹
• Platelet count decreased to 45 x 10⁹/L after 4 weeks of treatment
• Treatment was interrupted until platelet count recovered to >50 x 10⁹/L, due to increased risk of ICH, as per dosing guidelines¹

Treatment evolution:

• After 2 weeks, the platelet count did not improve, and the physician ordered a transfusion
• Platelet count improved to >50 x 10⁹/L, and treatment was resumed at a reduced dose of 100 mg once daily with monitoring¹
• After 6 months of treatment, repeated bone marrow biopsy showed a significant reduction in bone marrow mast cell aggregates, and a steady improvement in symptoms was reported

Patient history:

• Celine was diagnosed with ASM
• Initiated treatment with interferon alfa
• The treating physician decided to switch therapies due to unstable serum tryptase levels and tolerability issues

Introduction of AYVAKYT:

• The patient initiated AYVAKYT 200 mg once daily and platelet counts were monitored every 2 weeks for the first 8 weeks, as per dosing guidelines¹
• Platelet count at initiation was 188 x 10⁹/L
• Mild (Grade 1) facial oedema and peripheral oedema were observed within a week. Platelet count was 140 x 10⁹/L with no other cytopenias after 2 weeks of treatment
• The patient started to experience cognitive effects such as losing her keys and word-finding difficulty, so treatment was interrupted, as per dosing guidelines¹

Treatment evolution:

• After 2 weeks, the cognitive effects improved, and treatment was resumed at a reduced dose of 100 mg once daily with monitoring¹
• After 1 year of treatment, the patient remained on AYVAKYT therapy at 100 mg once daily and was tolerating it well

Patient history:

• Parminder presented with fatigue, mild ascites and maculopapular rash with 15% monocytes in circulating blood
• Initiated treatment with azacitidine (x4 cycles) but no improvement in symptoms was observed
• Re-evaluation confirmed a revised diagnosis of SM-AHN

Introduction of AYVAKYT:

• The patient initiated AYVAKYT 200 mg once daily, and platelet counts were monitored every 2 weeks for the first 8 weeks, as per dosing guidelines¹
• Worsening peripheral oedema (Grade 3) was observed after 3 months of treatment
• Treatment was interrupted until resolution to baseline, as per dosing guidelines¹

Treatment evolution:

• After 1 week, oedema resolved and treatment was resumed at a reduced dose of 100 mg once daily with monitoring¹
• After 2 years of treatment, the patient remained on AYVAKYT therapy at 100 mg once daily and was tolerating it well

Patient history:

• Adrienne was diagnosed with MCL
• Initiated treatment with cladribine (x2 cycles) to cytoreduce abnormally high mast cell counts. In parallel, an allogenic consult was initiated
• Symptoms improved but the patient was ruled out for bone marrow transplant due to the lack of available donors
• Additional treatment options were discussed with the patient

Introduction of AYVAKYT:

• The patient initiated AYVAKYT 200 mg once daily, and platelet counts were monitored every 2 weeks for the first 8 weeks as per dosing guidelines¹
• Platelet count at initiation was 95 x 10⁹/L
• After 6 weeks of treatment, 5% of bone marrow mast cells were detected. Thrombocytopenia improved to Grade 1 (160 x 10⁹/L)
• Grade 2 anaemia and Grade 2 periorbital oedema were observed, so treatment was interrupted for 1 week

Treatment evolution:

• After 1 week, adverse reactions improved, and treatment was resumed at a reduced dose of 100 mg once daily with monitoring¹
• After 1 year of treatment, repeated bone marrow biopsy showed an improvement in mast cell measures